En del af Watch Medier

MedWatchtorsdag2. februar 2023

  • Søg
  • Log ind
  • Medicinal & Biotek
  • Medico & Rehab
  • Laboratorie & Diagnostik
  • Høreapparater
  • Søg
  • Log ind
  • Seneste
  • Søg
  • Log ind
  • Medicinal & Biotek
  • Medico & Rehab
  • Laboratorie & Diagnostik
  • Høreapparater
  • Digital sundhed
  • Samfund
  • Mennesker
  • Sygdom & Sundhed
01.07.2013kl. 13.58

Medtech-CEO: Difficult to maintain prices

According to the CEO of a high-grossing Danish medtech company the price pressure in Europe and the U.S. is highly palpable – China is lurking on the horizon.
Foto: Colourbox
by Stefan Singh Kailay

Danish company Unomedical – owned by U.S. group ConvaTec – presented turnover of DKK 1.73 billion (USD 302 million) in 2012, an increase of 11.9 % compared with the year before. According to CEO John Magnus Lindskog the increase came mainly from Asia and the diabetes market.

“In 2012 we have had a nice growth in turnover, which is higher than our market growth. It was powered by a good performance in our CCC business (Continence & Critical Care), and we had an even bigger growth in our infusion business, which covers infusion sets for insulin pumps for diabetics,” he says, elaborating:

“It is driven by it being a therapy platform that offers treatment benefits for diabetics. There has been a significant growth in Europe and in the key market, USA, as well, just as we are starting to see penetration on some of the new markets in Asia.”

Under pressure

But he also explains that the challenge in 2012, 2013 and beyond is the price pressure the industry sees from the health care economy.

“The challenge is that the entire health care economy is under pressure in Europe and the U.S. We see that it becomes more and more difficult to maintain prices, and it obviously requires us to be able to make it more efficient. We are in a period in which there is a lot of focus on health care economies around the world, and we feel that as well.”

So far Unomedical has managed to streamline operations quite well. In 2009 operating profits were at DKK 43.04 million (USD 7.35 million). In 2012 it was up to DKK 423.27 million (USD 74 million).

Left Denmark

“We have improved by moving our production out of Denmark. We have established ourselves in low cost areas over a period of years. Moreover, we have – since becoming part of ConvaTec – achieved synergies, also on an administrative level. That has also helped drive the efficiency improvements we are now seeing the results of in the books.”

The CEO becomes more vague and taciturn as the talk turns to the company’s expectations for 2013.

“We expect to still see pressure on established markets in 2013. We will see a relatively low growth in Europe and the U.S., while we anticipate a stronger growth on new markets. I cannot be more specific about it for the time being.”

Unomedical’s owner, ConvaTec, is a rival to another Danish medtech group, Coloplast, on a number of areas. But John Magnus Lindskog says there are no products in his company’s portfolio that are in direct competition with Coloplast.

“There are a number of companies within the CCC business that I would view as rivals. Some of them are big international players, and then there are rivals from China that we see beginning to move into Western markets. Within infusion devices there are a few smaller companies that are our rivals.”

- translated by Martin Havtorn Petersen

Want to receive the latest news from Medwatch straight in your e-mail inbox? Sign up for our free english newsletter below.

Tilmeld dig vores nyhedsbrev

Vær på forkant med udviklingen. Få den nyeste viden fra branchen med vores nyhedsbrev.

!
Nyhedsbrevsvilkår

Forsiden lige nu

Foto: Mike Blake/Reuters/Ritzau Scanpix
Medicinal & Biotek

Eli Lilly løfter forventningerne til 2023

Eli Lilly har undervurderet sin tidligere prognose grundet en mulig skattemæssig ændring, og opjusterer derfor forventningerne til 2023. 
Foto: Ambu/pr
Medico & Rehab

Analytikere: Kerneforretningen driver Ambus organiske vækst

For abonnenter

Den gennemsnitlige sagsbehandlingstid på de 46 ansøgninger, som Medicinrådet behandlede fra industrien i 2022, var omtrent 22 uger.
Medicinal & Biotek

Medicinrådet er stadig for langsomme til at vurdere ny medicin

For abonnenter

Foto: Novo Nordisk / Pr
Medicinal & Biotek

Efter sløv start haler diabetestablet fra Novo Nordisk ind på topsællert

For abonnenter

Photo: Boehringer Ingelheim / Pr
Medicinal & Biotek

Boehringer Ingelheim flytter dansk hovedkvarter til Islands Brygge

For abonnenter

Foto: Louise Herrche Serup
Samfund

Dansk Erhverv har lavet en ny life science-politik: Vi kan nå endnu længere, hvis vi justerer rammevilkårerne

For abonnenter

Seneste nyt

  • Eli Lilly løfter forventningerne til 2023 – 13.17
  • Analytikere: Kerneforretningen driver Ambus organiske vækst – 13.02
  • Efter sløv start haler diabetestablet fra Novo Nordisk ind på topsællert – 12.07
  • Medicinrådet er stadig for langsomme til at vurdere ny medicin – 11.38
  • Dansk Erhverv har lavet en ny life science-politik: Vi kan nå endnu længere, hvis vi justerer rammevilkårerne – 11.14
  • Boehringer Ingelheim flytter dansk hovedkvarter til Islands Brygge – 10.52
  • Fluoguide skifter finansdirektør efter få måneder – 09.58
  • Sydbank ser kinesisk modvind give afdæmpet start på året for Coloplast – 09.32
  • Jyske om Demant-regnskab i næste uge: Fokus bliver på forventningerne til 2023 – 08.10
  • Finansmanden Kronborg kan opfylde børsdrøm for biotekselskab – 06.57
  • Kronborg om dobbeltjob: Forudsætter en vis fleksibilitet – 1. feb.
  • Novo Holdings toppede listen over skattebetalere i 2021 – 1. feb.
  • Fruergaard: Fedmemarkedet er åbenlyst en stor mulighed – 1. feb.
  • GN tabte markedsandele hos amerikanske veteraner i december – 1. feb.
  • GSK falder trods stærkt kvartal og opløftende prognose for 2023 – 1. feb.
Flere nyheder

Job

  • Supply Chain Manager

  • Regulatory Affairs Professional

  • Sr. Director, Drug Safety Physician

  • Lead Data Architect

  • Application Manager

  • Senior Regulatory Affairs Professional

  • Commercial Director

  • Erfaren Patentrådgiver

  • Specialist til udbud på lægemidler til danske sygehuse

  • Head of Regulatory Affairs Danmark

  • Application Manager

  • Clinical Operational Associate

Se flere jobs

Watch Job

  • Scrum Master with a practical approach

  • Business Controller til DAHL Advokatpartnerselskab i Jylland

  • Tilbudschef - NCC Renovering Vest

  • Jurister søges til Corporate Legal i Danmarks Eksport & Investeringsfond

  • Forvaltningsservicechef i Vestforbrænding

Se flere jobs

Job

  • Supply Chain Manager

  • Regulatory Affairs Professional

  • Sr. Director, Drug Safety Physician

  • Lead Data Architect

  • Application Manager

  • Senior Regulatory Affairs Professional

  • Commercial Director

  • Erfaren Patentrådgiver

  • Specialist til udbud på lægemidler til danske sygehuse

  • Head of Regulatory Affairs Danmark

  • Application Manager

  • Clinical Operational Associate

Se flere jobs

Kolofon

MedWatch
Søg

Sektioner

  • Medicinal & Biotek
  • Medico & Rehab
  • Laboratorie & Diagnostik
  • Høreapparater
  • Digital sundhed
  • Samfund
  • Mennesker
  • Sygdom & Sundhed
  • Sitemap
  • RSS feeds

Redaktør

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tlf.: +45 3330 8387

Ansv. chefredaktør

Anders Heering

Udgiver

JP/Politikens Hus A/S

Annonceafdeling

annoncering@infowatch.dk

Tlf.: +45 7077 7441

Annoncering

Jobannoncering

job@infowatch.dk

Tlf.: +45 7077 7441

Job

Abonnement

Prøv MedWatch gratis eller få tilbud på et abonnement, der passer til lige netop dig eller din virksomhed.

medwatch@infowatch.dk

Tlf.: +45 7077 7441

Læs mere om abonnement her

Adresse

MedWatch

Rådhuspladsen 37

1785 København V

Tlf.: +45 3330 8370

Retningslinjer

  • Persondatapolitik

Copyright © MedWatch — Alt materiale på denne side er omfattet af gældende lov om ophavsret

Microsoft er i gang med at udfase Internet Explorer – det er vi derfor også.
Vi anbefaler en af følgende browsere for en bedre oplevelse. Klik på et af ikonerne for at downloade en ny browser.

Med venlig hilsen,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge